financetom
Business
financetom
/
Business
/
IAMGOLD Q3 Adjusted Earnings, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IAMGOLD Q3 Adjusted Earnings, Revenue Increases
Nov 4, 2025 3:30 PM

06:01 PM EST, 11/04/2025 (MT Newswires) -- IAMGOLD ( IAG ) reported Q3 adjusted earnings late Tuesday of $0.30 per share, up from $0.18 a year earlier.

Analysts polled by FactSet expected $0.22.

Revenue for the quarter ended Sept. 30 was $706.7 million, up from $438.9 million a year ago.

Three analysts surveyed by FactSet expected $667.1 million.

Shares of the company rose 5.8% in recent after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump administration announces Boeing deals in Central Asia
Trump administration announces Boeing deals in Central Asia
Nov 6, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump's administration announced Thursday new deals to sell up to 37 Boeing ( BA ) airplanes to airlines in the Central Asian nations of Kazakhstan, Tajikistan and Uzbekistan. The Commerce Department said Kazakhstan flag carrier Air Astana plans to buy up to 15 Boeing 787-9 Dreamliners to grow and modernize its fleet. The orders were...
Structure Therapeutics Q3 loss widens to $65.7 mln
Structure Therapeutics Q3 loss widens to $65.7 mln
Nov 6, 2025
Overview * Structure Therapeutics ( GPCR ) reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024 * Company maintains strong cash position of $799 mln, funding operations through 2027 * Phase 1 study for oral amylin receptor agonist ACCG-2671 to start by year-end 2025 Outlook * Structure Therapeutics ( GPCR ) expects topline data from ACCESS...
Denali Therapeutics Q3 net loss widens to $126.9 mln
Denali Therapeutics Q3 net loss widens to $126.9 mln
Nov 6, 2025
Overview * Denali Q3 net loss widens to $126.9 mln from $107.2 mln last year * Operating expenses increased due to R&D and commercial launch preparations * FDA extends tividenofusp alfa review timeline to April 2026 from January Outlook * Denali expects to launch tividenofusp alfa for Hunter syndrome after FDA review by April 2026 * Company plans global Phase...
Mercer Q3 revenue misses analyst estimates as trade uncertainties hurt demand
Mercer Q3 revenue misses analyst estimates as trade uncertainties hurt demand
Nov 6, 2025
Overview * Mercer Q3 revenue declines 9% yr/yr, missing analyst expectations * Operating EBITDA turns negative, impacted by lower pulp sales and higher fiber costs * Company advances cost-saving initiatives to improve liquidity and efficiency Outlook * Mercer expects weak pulp prices to persist in Q4 2025 * Company anticipates modest lumber price increase in Europe in Q4 2025 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved